TOP 15! Take stock of the highest-paid female CEOs in the biopharmaceutical industry

According to statistics, less than 10% of the CEOs of many biopharmaceutical companies are women.
following is a list of the top 15 female CEOs currently in the biopharmaceutical sector.
No.1 |。 Martine Rothblatt, Inc.: United Therapeutics Rothblatt is the founder, chairman and CEO of United Therapeutics.
, Rothblatt is also a lawyer and holds an MBA.
her total compensation for 2019 was $45.65 million.
Rothblatt founded United Therapeutics in 1996 and led the company in the development of a number of pulmonary hypertension therapy drugs, including three querclin products, Remodulin (Querin neal Injection), Tyvaso (Quernier Inhalation Solution), and Orenitram (Queantran Neal Slow Release Tablets).
, United Therapeutics is also actively working on medical issues related to organ transplantation.
No.2 |。 Elizabeth (Liz) Barrett: UroGen Pharma Barrett is president and CEO of UroGen Pharma, which will pay $25.9 million in 2019.
barrett held leadership positions at Novarce, Pfizer, Cephalon and Johnson and Johnson before he held his current position.
her bachelor's degree is science and her graduate degree is business administration.
May 2020, UroGen announced that it was evaluating the results of Jermyto's critical Phase III OLYMPUS trial for the treatment of low-level upper urethroid skin cancer (LG-UTUC) in adults.
results showed a full remission rate (CR) of 59 per cent for Jelmyto's treatment and 84 per cent for the 12-month remission assessed by Kaplan-Meier.
No.3 |。 Deborah Dunsire, Inc.: Lingbei Pharmaceuticals Dunsire is a M.D. and has been President and CEO of Lundbeck in Neuroscience since 2018.
her 2019 salary of $21.2 million.
, she was President and CEO of XTuit Pharmaceuticals, FORUM Pharmaceuticals and Millennium Pharmaceuticals.
is a global pharmaceutical company focused on discovering and developing innovative treatments for brain diseases.
has launched a range of drugs in China to treat brain diseases, including Lesp (depression), Epishen (Alzheimer's disease), Magpies (depression) and Delixin (depression).
No.4 |。 Heather Bresch, Inc.: Mylan Bresch was CEO of Mylan, the world's leading generic pharmaceutical company, from 2012 to 2020.
her total compensation for 2019 was $18.51 million.
Bresch is the first female CEO of a Fortune 500 pharmaceutical company.
stepped down as CEO in 2020 after Melanie merged with Pfizer's Upjohn unit.
under the previous merger agreement, Pfizer would own 57 per cent of the combined company, while Mylan would own 43 per cent.
No.5 |。 Jacqualyn Fouse Inc.: Agios Pharmaceuticals Fouse is the Director and CEO of Agios Pharmaceuticals.
her 2019 salary of $16.6 million.
, he served as President and Chief Operating Officer of Celgene and Chief Financial Officer of Bunge Limited.
has a Ph.D. in finance.
October, Agios withdrew a sales license application for the acute leukemia drug Tibsovo (ivosidenib) in the European market for recurring or refr treatable acute myeloid leukemia (R/R AML) with a mutation in IDH1 (isocric acid dehydrogenase-1).
the drug has been approved by the FDA for the allergy, European regulators do not appear to agree with the FDA's decision to approve it.
No.6 |。 Cynthia Collins: Editas Medicine Collins is CEO of Editas Medicine.
her 2019 salary of $14.49 million.
Collins previously served as CHIEF Executive Officer of the Human Life, Cell Therapy and Laboratories businesses of General Electric Healthcare Life Sciences, Clarient Diagnostics, GenVec and Sequoia Pharmaceuticals.
her undergraduate major is microbiology and her master's degree is business administration.
March this year, Eljian and Editas Medicine jointly announced that the gene therapy AGN-151587 (EDIT-101) had completed the first phase 1/2 of the clinical treatment of Leber's congenital melanotheptic type 10 (LCA10), a genetically blind disease.
is the world's first CRISPR genome-editing drug to be drugd in the human body.
No.7 |。 Emma Walmsley: GlaxoSmithKline has been CEO of GlaxoSmithKline since 2017.
her total salary for 2019 was 8.37 million pounds ($10.7 million).
Walmsley joined GlaxoSmithKline in 2010 after 17 years at L'Oreal.
Walmsley took office, he has pushed ahead with reforms, divestitures and plans to focus 80 per cent of his research and development spending on core businesses - respiratory diseases, HIV, oncology and immune inflammation.
November, GlaxoSmithKline (GSK) and Medicago jointly announced the launch of Phase 2/3 clinical trials to assess the effectiveness, safety and immunogenicity of CoVLP, a candidate vaccine derived from plants.
No.8 |。 Alexandria Forbes: Meira GTx Forbes is President and CEO of Meira GTx.
her 2019 salary of $8.48 million.
forbes worked at Kadmon Holdings, Meadowvale Asset Management and Sivik Global Healthcare prior to his current role.
graduated from Oxford University with a Ph.D. in Molecular Genetics.
Meira GTx is a biopharmaceutical company focused on gene therapy research and development, focusing on ophthalmological diseases, salivary gland diseases and neurodegenerative diseases.
the company's core strengths are virus vector design, optimization, gene therapy production, and transformational gene regulation.
No.9 |。 Emily Leproust: Twist Bioscience Leproust is CEO of Twist Bioscience.
her 2019 salary of $8.13 million.
leproust worked at Aguilent Technologies before joining Twist Bioscience.
holds a Ph.D. in Organic Chemistry.
November, Twist Bioscience Corporation and Western Digital announced an alliance with Microsoft to advance the field of DNA data storage.
No.10 |。 Reshma Kewalramani: Vertex Pharmaceuticals Kewalramani is CEO and President of Vertex Pharmaceuticals.
her 2019 salary of $6.82 million.
Kewalramani joined Vertex Pharmaceuticals in 2017 as Senior Vice President of Late Development CMO and as CEO from April 2020.
she had worked at Amgen for 12 years.
, a M.D., also studied management at Harvard Business School.
December, CRISPR Therapeutics and Vertex Pharmaceuticals released the latest clinical data for CRISPR/Cas9 gene editing therapy CTX001.
data, the company's CTX001 is expected to be a potential one-off healing treatment for patients with TDT and severe SCD.
No.11 |。 Sheila Gujrathi Company: Gossamer Bio Gujrathi is the co-founder, president and CEO of Gossamer Bio.
her 2019 salary of $6.25 million.
co-founding Gossamer Bio, Gujrathi served as Vice President of the Global Clinical Development Group for CMO and Bristol Myers Squibb immunology at Receptos.
she is also a M.D.
2019, Gossamer is officially listed on the Nasdaq Exchange with an issue price of $16.00 per share.
Gossamer Bio raised $276 million by issuing a total of 17,250,000 shares.
No.12 |。 Sharon Mates, Inc.: Intra-Cellular Therapies Mates is the co-founder, chairman, president and CEO of Intra-Cellular Therapies.
her 2019 salary of $4.72 million.
in his current role, Mates co-founded Fusion Genetics and served as president and board member of the North American Vaccine Corporation.
holds a Ph.D. from the University of Washington.
net profit attributable to common shareholders of the parent company was negative $148 million, up 4.77 percent year-on-year and operating income of $606,000, according to the company's fiscal 2019 annual report released in March.
No.13 |。 Maria Fardis Corporation: Iovance Biotherapeutics Fardis has been CEO and President of Iovance Biotherapeutics since 2016.
her total compensation for 2019 was $4.11 million.
Fardis previously served as chief operating officer of Aperta Pharma and worked at Pharmacyclics and Gilead Science.
holds a Ph.D. in Organic Chemistry and an MBA.
Lifileucel (LN-144) is an immunotherapy specifically for melanoma based on auto-tumor-immersed lymphocytes (TIL) developed by Iovance, a T-cell-based supercytotherapy (ACT).
test results show that TILs therapy has the ability to achieve long-lasting remission of advanced metastasis non-small cell lung cancer.
No.14 |。 Nancy Simonian: Syros Pharmaceuticals Simonian is President and Founding CEO of Syros Pharmaceuticals.
her 2019 salary of $3.61 million.
she previously held leadership positions at Millenium Pharmaceuticals and Biogen.
Simonian is M.D. and has worked academically and clinically at Harvard Medical School and Massachusetts General Hospital.
Syros Pharmaceuticals is a pharmaceutical company focused on developing innovative drugs to control gene expression, and its star product is the company's first selective refracitate α (RAR alpha) agonist SY-1425 for the treatment of acute myeloid leukemia.
No.15 |。 Rachel King, co-founder and CEO of Glyco Mimetics, was paid $2.69 million in 2019.
King previously served as a resident executive at New Enterprise Associates, served as Senior Vice President of Novartic and was a core member of Genetic Therapy.
holds a Bachelor of Business Administration degree from Harvard Business School.
January, the company treated GlycoMimetics with acute myeloid leukemia (AML) drugs Uproleselan and GMI-16